Cymabay Therapeutics Inc is a biopharmaceutical company in the clinical stage, dedicated to developing therapies aimed at liver and chronic diseases. Its flagship product, seladelpar, targets primary biliary cholangitis, a liver disease, through a specific receptor activation. Additionally, Cymabay is working on a treatment for type 1 diabetes. Originally known as Metabolex, Inc., the company was founded in 1988 and is based in Fremont, California.
Tuesday's top analyst upgrades and downgrades included Amgen, CF Industries, Coterra Energy, CymaBay Therapeutics, Eaton, Marriott, Monster Beverage, Mosaic, Nutrien, Public Service Enterprise, Urban Outfitters and Wayfair.
Friday's top analyst upgrades and downgrades included Advanced Micro Devices, Asana, Etsy, Exact Sciences, Guardant Health, Hilton Worldwide, Meta Platforms, MongoDB, Salesforce, ServiceNow, Sysco and Teladoc Health.
Wednesday's top analyst upgrades and downgrades included Bluebird Bio, Boeing, Coinbase Global, Costco Wholesale, Envista, Merck, New Fortress Energy, NexTier Oilfield Solutions, Radius Global Infrastructures, Regions Financial and Wayfair.
These are five biotech and medtech stocks for very aggressive accounts that look to get shares count leverage on companies that have sizable upside potential.
Lee Jackson CymaBay Therapeutics posted a huge gain to start off the week after the company reported results from a late-stage clinical study for the treatment of primary biliary cholangitis.
Chris Lange CymaBay Therapeutics shares more than doubled on Tuesday after the company announced its first-quarter results, along with a corporate update.
Chris Lange 